A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
NCT06313996 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2026-03-18
Summary
The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma.
Conditions
- Relapsed or Refractory Follicular Lymphoma
Interventions
- DRUG
-
Specified dose on specified days
- DRUG
-
Doxorubicin
Specified dose on specified days
- DRUG
-
Vincristine
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
-
Celgene Corporation
collaborator INDUSTRY -
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-29
- Primary Completion
- 2031-10-16
- Completion
- 2031-10-16
- FDA Drug
- Yes
More Related Trials
-
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
NCT06132503 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT02631577 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
NCT05848765 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
NCT02082977 ·Status: TERMINATED ·Phase: PHASE1
-
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068 ·Status: COMPLETED ·Phase: PHASE1
-
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
NCT06489808 ·Status: RECRUITING ·Phase: PHASE2
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
NCT06561048 ·Status: RECRUITING ·Phase: PHASE3
-
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
NCT04156828 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502 ·Status: RECRUITING ·Phase: PHASE3
-
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
NCT06158386 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT06160843 ·Status: RECRUITING ·Phase: PHASE2
-
Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01719250 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT01481129 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
NCT05615636 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
NCT03610724 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
NCT03568461 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
NCT02249429 ·Status: COMPLETED ·Phase: PHASE2
-
PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
NCT03120000 ·Status: WITHDRAWN ·Phase: PHASE2
-
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
NCT04379167 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
NCT00531284 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
NCT03150329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
NCT05418088 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
NCT03630159 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
NCT02258555 ·Status: TERMINATED ·Phase: PHASE1